Hepatitis B, Chronic
Conditions
Brief summary
Globally, an estimated 257 million individuals have chronic hepatitis B-virus infection (CHB). In the absence of treatment 15-40% of these will progress to liver cirrhosis and/or hepatocellular carcinoma. Oral antiviral treatment suppresses the virus and improves prognosis, but less than 0.5% per year achieve a functional cure (i.e. HBsAg loss). One remaining controversy, therefore, is whether antiviral treatment must continue life-long. Observational studies have assessed stopping antiviral treatment after years of viral suppression; however, HBsAg loss has rarely been seen. But interestingly, a few small trials that chose watchful waiting instead of re-initiation of treatment when reactivation occurred, achieved 40% HBsAg loss during 6 years follow-up. The present proposal is a randomized controlled trial that will assess the safety, efficacy, and cost-effectiveness of treatment discontinuation - and delayed restart - in HBeAg negative CHB. The study is sufficiently powered to address the hypotheses, and a pilot study that demonstrates feasibility has been performed. Patients will be enrolled at 12 Norwegian hospitals, in addition to our collaborating institution in Ethiopia - the largest CHB treatment center in sub-Saharan Africa. If the study shows that discontinuation is safe and effective, it will directly impact both national and international treatment guidelines. Main objective: -To study whether stopping nucleoside analogue (NA) therapy - and delaying re-start - can trigger an immune response and set off a functional cure (viz HBsAg loss) Secondary objectives: * Assess whether stopping NA therapy - and delaying re-start - leads to a higher chance of HBsAg loss * Assess the safety of stopping NA therapy - and delaying re-start - in terms of hepatic decompensation, fibrosis progression, and/or adverse events * Study whether stopping NA therapy - and delaying re-start - leads to a higher chance of sustained off-therapy immune control (low viral load and normal ALT) * Assess the quality of life and cost-effectiveness of stopping NA therapy - and delaying re-start * Identify predictors of HBsAg loss
Interventions
OTHERStop of therapy
The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
Sponsors
University Hospital, Akershus
Addis Ababa University
St. Paul's Hospital Millennium Medical College, Ethiopia
South-Eastern Norway Regional Health Authority, Norway
Bærum Hospital, Norway
Drammen Hospital, Norway
Tønsberg Hospital, Norway
Helse Stavanger HF
Ålesund Hospital, Norway
Bodø Hospital, Norway
Hvidovre University Hospital
Karolinska University Hospital
Oslo University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adults (18-70 years) with HBeAg negative chronic hepatitis B * HBeAg negative at start of antiviral therapy * Treated minimum 2 years with either tenofovir or entecavir without interruption (i.e. no self-reported episodes of ≥2 weeks off therapy) * Full viral suppression \>2 years: at least 3 measurements at least 6 months apart with at least 24 months between the first and last measurement. * Most recent liver fibrosis assessment, performed within the past 12 months, does not show advanced fibrosis (i.e. Metavir score \<F3 or Fibroscan \<9 kPa). For the (few) patients who lack pre-treatment fibrosis assessment, a more conservative Fibroscan threshold of \<8 kPa will apply.
Exclusion criteria
* A history of decompensated liver disease, either by clinical signs (ascites, encephalopathy, portal hypertension, jaundice) or suggestive laboratory results (total bilirubin \>38 umol/L, INR \>1.5, platelets \<75,000/mm3, serum albumin \<30 g/L). * Any previous diagnosis of cirrhosis, either by liver biopsy (Metavir score F4) or elastography (Fibroscan \>12 kPa). Elastography results with concomitant ALT \>200 U/L are not considered. * Previous hepatocellular carcinoma (HCC). * Co-infections with HIV, hepatitis C or hepatitis D. * Other disease or medication that can interfere with the study (e.g. ongoing alcohol or illicit drug abuse, immunosuppressive medication, other active liver disease, or any other condition which in the opinion of the physician is incompatible with participation)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HBsAg loss | Within 3 years after stopping therapy | Undetectable HBsAg measured by a standard assay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to re-start of antiviral therapy | Within 3 years after stopping therapy | Time from randomization to re-start of therapy according to the specified criteria |
| Severe unintended medical events | Within 3 years after stopping therapy | Liver failure or other liver-related grade 4/5 SAEs |
| Time to HBsAg loss | Within 3 years after stopping therapy | Time from randomization to undetectable HBsAg |
| Changes in health-related quality of life | Within 3 years after stopping therapy | Changes in the EuroQol standardized measure of health status (EQ-5D-5L) score. The summary index (from 0 to 1) as described by the manufacturer (euroqol.org) will be employed. |
| Liver fibrosis evolution | Within 3 years after stopping therapy | Changes in transient elastography from baseline |
| Immune control | Within 3 years after stopping therapy | Sustained off-therapy response viz HBV DNA \<2000 IU/ml and ALT \<40 U/L |
Countries
Denmark, Ethiopia, Norway, Sweden
Outcome results
None listed